IRAK1 and breast carcinoma: Immunohistochemistry (IHC) analyses of two commercial tissue microarrays (TMAs) (IMH364 and BR1505), which comprises two independent cohorts of breast tumour specimens with different subtypes confirmed the upregulation of IRAK1 protein expression in breast cancers, in particular among TNBCs (Fig. 1b, P<0.01, Tukey's multiple comparisons test).